Terms: = Ovarian cancer AND TGFBR2, AAT3, 7048, ENSG00000163513, P37173, TGFbeta-RII, RIIC, TAAD2, FAA3, TGFR-2, MFS2, HNPCC6
15 results:
1. Modulatory effect of pomegranate peel extract on key regulators of ovarian cellular processes
Kolesarova A; Baldovska S; Kohut L; Vasicek J; Ivanisova E; Arvay J; Duracka M; Roychoudhury S
Front Endocrinol (Lausanne); 2023; 14():1277155. PubMed ID: 38027211
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR-mediated tgfbr2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
[TBL] [Abstract] [Full Text] [Related]
3. Predictors of malignancy in incidental adnexal lesions identified on CT in patients with prior non-ovarian cancer.
Shinagare AB; Gujrathi I; Cochon L; Burk KS; Sadowski E; Khorasani R
Abdom Radiol (NY); 2022 Jan; 47(1):320-327. PubMed ID: 34468797
[TBL] [Abstract] [Full Text] [Related]
4. Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
Monsivais D; Peng J; Kang Y; Matzuk MM
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3883-3892. PubMed ID: 30655341
[TBL] [Abstract] [Full Text] [Related]
5. Assessment of variation in immunosuppressive pathway genes reveals tgfbr2 to be associated with risk of clear cell ovarian cancer.
Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
[TBL] [Abstract] [Full Text] [Related]
6. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast cancer Association Consortium.
Lei J; Rudolph A; Moysich KB; Behrens S; Goode EL; Bolla MK; Dennis J; Dunning AM; Easton DF; Wang Q; Benitez J; Hopper JL; Southey MC; Schmidt MK; Broeks A; Fasching PA; Haeberle L; Peto J; Dos-Santos-Silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Marmé F; Guénel P; Truong T; Bojesen SE; Flyger H; Nielsen SF; Nordestgaard BG; González-Neira A; Menéndez P; Anton-Culver H; Neuhausen SL; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Hamann U; Nevanlinna H; Fagerholm R; Dörk T; Bogdanova NV; Mannermaa A; Hartikainen JM; ; ; Van Dijck L; Smeets A; Flesch-Janys D; Eilber U; Radice P; Peterlongo P; Couch FJ; Hallberg E; Giles GG; Milne RL; Haiman CA; Schumacher F; Simard J; Goldberg MS; Kristensen V; Borresen-Dale AL; Zheng W; Beeghly-Fadiel A; Winqvist R; Grip M; Andrulis IL; Glendon G; García-Closas M; Figueroa J; Czene K; Brand JS; Darabi H; Eriksson M; Hall P; Li J; Cox A; Cross SS; Pharoah PD; Shah M; Kabisch M; Torres D; Jakubowska A; Lubinski J; Ademuyiwa F; Ambrosone CB; Swerdlow A; Jones M; Chang-Claude J
Hum Genet; 2016 Jan; 135(1):137-54. PubMed ID: 26621531
[TBL] [Abstract] [Full Text] [Related]
7. Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.
Kohan-Ivani K; Gabler F; Selman A; Vega M; Romero C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):47-58. PubMed ID: 26091707
[TBL] [Abstract] [Full Text] [Related]
8. Association study of tgfbr2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure, and early menopause among Chinese Han women.
Ma X; Chen Y; Zhao X; Chen J; Shen C; Yang S
Medicine (Baltimore); 2014 Oct; 93(20):e93. PubMed ID: 25365407
[TBL] [Abstract] [Full Text] [Related]
9. Metastatic tumor evolution and organoid modeling implicate tgfbr2 as a cancer driver in diffuse gastric cancer.
Nadauld LD; Garcia S; Natsoulis G; Bell JM; Miotke L; Hopmans ES; Xu H; Pai RK; Palm C; Regan JF; Chen H; Flaherty P; Ootani A; Zhang NR; Ford JM; Kuo CJ; Ji HP
Genome Biol; 2014 Aug; 15(8):428. PubMed ID: 25315765
[TBL] [Abstract] [Full Text] [Related]
10. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.
Riester M; Wei W; Waldron L; Culhane AC; Trippa L; Oliva E; Kim SH; Michor F; Huttenhower C; Parmigiani G; Birrer MJ
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24700803
[TBL] [Abstract] [Full Text] [Related]
11. Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes.
Huang RL; Chao CF; Ding DC; Yu CP; Chang CC; Lai HC; Yu MH; Liu HS; Chu TY
Cancer Genet Cytogenet; 2004 Sep; 153(2):108-14. PubMed ID: 15350299
[TBL] [Abstract] [Full Text] [Related]
12. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, tgfbeta-rii, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract] [Full Text] [Related]
13. Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Seitz S; Wassmuth P; Plaschke J; Schackert HK; Karsten U; Santibanez-Koref MF; Schlag PM; Scherneck S
Genes Chromosomes Cancer; 2003 May; 37(1):29-35. PubMed ID: 12661003
[TBL] [Abstract] [Full Text] [Related]
14. Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (tgfbr2) in sporadic ovarian cancer.
Alvi AJ; Rader JS; Broggini M; Latif F; Maher ER
Mol Pathol; 2001 Aug; 54(4):240-3. PubMed ID: 11477138
[TBL] [Abstract] [Full Text] [Related]
15. Mapping of chromosome 3p deletions in human epithelial ovarian tumors.
Lounis H; Mes-Masson AM; Dion F; Bradley WE; Seymour RJ; Provencher D; Tonin PN
Oncogene; 1998 Nov; 17(18):2359-65. PubMed ID: 9811467
[TBL] [Abstract] [Full Text] [Related]
